Three Years Survival Outcome And Continued Cemiplimab (CEMI) Beyond Progression With The Addition Of Chemotherapy (Chemo) For Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): The EMPOWER-Lung 1 Trial
| dc.contributor.author | Ozguroglu, M. | |
| dc.contributor.author | Kilickap, S. | |
| dc.contributor.author | Sezer, A. | |
| dc.contributor.author | Gumus, M. | |
| dc.contributor.author | Bondarenko, I. | |
| dc.contributor.author | Gogishvili, M. | |
| dc.contributor.author | Nechaeva, M. | |
| dc.contributor.author | Schenker, M. | |
| dc.contributor.author | Cicin, I. | |
| dc.contributor.author | Ho, G. F. | |
| dc.contributor.author | Kulyaba, Y. | |
| dc.contributor.author | Dvorkin, M. | |
| dc.contributor.author | Zyuhal, K. | |
| dc.contributor.author | Scheusan, R. I. | |
| dc.contributor.author | Li, S. | |
| dc.contributor.author | Pouliot, J-F. | |
| dc.contributor.author | Seebach, F. | |
| dc.contributor.author | Lowy, I. | |
| dc.contributor.author | Gullo, G. | |
| dc.contributor.author | Rietschel, P. | |
| dc.date.accessioned | 2023-01-02T07:38:02Z | |
| dc.date.available | 2023-01-02T07:38:02Z | |
| dc.date.issued | 2022 | |
| dc.identifier.endpage | 1421 | en_US |
| dc.identifier.issn | 0923-7534 | en_US |
| dc.identifier.issue | 7 | en_US |
| dc.identifier.startpage | 1421 | en_US |
| dc.identifier.uri | https://reader.elsevier.com/reader/sd/pii/S0923753422039345?token=71A2014D03917840BAA6B9F5FF6D27514DC3A1A11C5ACA71B082418092AA82EE053976F23B46425060D9A4E2069A7D6B&originRegion=eu-west-1&originCreation=20230102073637 | |
| dc.identifier.uri | http://hdl.handle.net/11727/8488 | |
| dc.identifier.volume | 33 | en_US |
| dc.identifier.wos | 000866211602466 | en_US |
| dc.language.iso | eng | en_US |
| dc.relation.isversionof | 10.1016/j.annonc.2022.08.056 | en_US |
| dc.relation.journal | ANNALS OF ONCOLOGY | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Three Years Survival Outcome And Continued Cemiplimab (CEMI) Beyond Progression With The Addition Of Chemotherapy (Chemo) For Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): The EMPOWER-Lung 1 Trial | en_US |
| dc.type | Conference Object | en_US |